BNP Paribas Financial Markets Takes $9.08 Million Position in 10x Genomics, Inc. (NASDAQ:TXG)

BNP Paribas Financial Markets purchased a new position in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 632,531 shares of the company's stock, valued at approximately $9,083,000. BNP Paribas Financial Markets owned about 0.52% of 10x Genomics at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in TXG. Algert Global LLC grew its holdings in 10x Genomics by 78.1% during the 4th quarter. Algert Global LLC now owns 660,620 shares of the company's stock worth $9,487,000 after acquiring an additional 289,662 shares in the last quarter. RA Capital Management L.P. bought a new position in 10x Genomics during the 4th quarter worth about $47,092,000. Jane Street Group LLC grew its holdings in 10x Genomics by 48.4% during the 4th quarter. Jane Street Group LLC now owns 360,257 shares of the company's stock worth $5,173,000 after acquiring an additional 117,449 shares in the last quarter. Voleon Capital Management LP bought a new position in 10x Genomics during the 4th quarter worth about $205,000. Finally, PDT Partners LLC grew its holdings in 10x Genomics by 176.4% during the 4th quarter. PDT Partners LLC now owns 354,958 shares of the company's stock worth $5,097,000 after acquiring an additional 226,513 shares in the last quarter. 84.68% of the stock is currently owned by institutional investors.

Insider Activity at 10x Genomics

In related news, CEO Serge Saxonov sold 5,092 shares of the firm's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $11.07, for a total transaction of $56,368.44. Following the sale, the chief executive officer now owns 879,482 shares in the company, valued at approximately $9,735,865.74. This trade represents a 0.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Benjamin J. Hindson sold 4,573 shares of the firm's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $11.07, for a total transaction of $50,623.11. Following the sale, the insider now owns 335,324 shares in the company, valued at approximately $3,712,036.68. This represents a 1.35% decrease in their position. The disclosure for this sale can be found here. 9.39% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms have commented on TXG. Leerink Partnrs lowered shares of 10x Genomics from a "strong-buy" rating to a "hold" rating in a research report on Thursday, February 13th. Leerink Partners lowered shares of 10x Genomics from an "outperform" rating to a "market perform" rating and decreased their price target for the company from $25.00 to $12.00 in a research report on Thursday, February 13th. Barclays decreased their price target on shares of 10x Genomics from $15.00 to $12.00 and set an "overweight" rating for the company in a research report on Thursday, April 10th. UBS Group decreased their price target on shares of 10x Genomics from $14.00 to $12.00 and set a "neutral" rating for the company in a research report on Tuesday. Finally, Morgan Stanley decreased their price target on shares of 10x Genomics from $28.00 to $26.00 and set an "overweight" rating for the company in a research report on Friday, February 14th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $17.65.

10x Genomics Stock Down 5.5%

Shares of NASDAQ:TXG traded down $0.53 during midday trading on Wednesday, reaching $9.12. The company's stock had a trading volume of 4,652,572 shares, compared to its average volume of 2,350,971. The firm has a market capitalization of $1.12 billion, a PE ratio of -6.00 and a beta of 1.94. 10x Genomics, Inc. has a twelve month low of $6.78 and a twelve month high of $27.49. The stock has a fifty day moving average of $8.88 and a 200 day moving average of $12.48.

10x Genomics (NASDAQ:TXG - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.36) earnings per share for the quarter, topping analysts' consensus estimates of ($0.45) by $0.09. The firm had revenue of $154.88 million for the quarter, compared to analyst estimates of $131.91 million. 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. The business's quarterly revenue was down 2.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.50) earnings per share. Sell-side analysts anticipate that 10x Genomics, Inc. will post -1.43 earnings per share for the current fiscal year.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.